182 related articles for article (PubMed ID: 27030639)
1. Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa.
Gao F; Huang C; Zhang Y; Sun R; Zhang Y; Wang H; Zhang S
Cancer Biol Ther; 2016 Jun; 17(6):595-8. PubMed ID: 27030639
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Advanced Malignant Uterine Perivascular Epithelioid Cell Tumor with mTOR Inhibitors: Single-institution Experience and Review of the Literature.
Starbuck KD; Drake RD; Budd GT; Rose PG
Anticancer Res; 2016 Nov; 36(11):6161-6164. PubMed ID: 27793946
[TBL] [Abstract][Full Text] [Related]
3. A rare metastatic mesenteric malignant PEComa with TSC2 mutation treated with palliative surgical resection and nab-sirolimus: a case report.
Meredith L; Chao T; Nevler A; Basu Mallick A; Singla RK; McCue PA; Bowne WB; Jiang W
Diagn Pathol; 2023 Apr; 18(1):45. PubMed ID: 37041531
[TBL] [Abstract][Full Text] [Related]
4. Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa.
Italiano A; Delcambre C; Hostein I; Cazeau AL; Marty M; Avril A; Coindre JM; Bui B
Ann Oncol; 2010 May; 21(5):1135-7. PubMed ID: 20215136
[No Abstract] [Full Text] [Related]
5. Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice.
Pawaskar DK; Straubinger RM; Fetterly GJ; Hylander BH; Repasky EA; Ma WW; Jusko WJ
Cancer Chemother Pharmacol; 2013 May; 71(5):1231-40. PubMed ID: 23455452
[TBL] [Abstract][Full Text] [Related]
6. First pancreatic perivascular epithelioid cell tumor (PEComa) treated by mTOR inhibitor.
Gondran H; Thebaud E; Moreau A; Le Rhun M; Touchefeu Y; Regenet N; Musquer N
Pancreatology; 2019 Jun; 19(4):566-568. PubMed ID: 31130397
[TBL] [Abstract][Full Text] [Related]
7. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.
Wagner AJ; Malinowska-Kolodziej I; Morgan JA; Qin W; Fletcher CD; Vena N; Ligon AH; Antonescu CR; Ramaiya NH; Demetri GD; Kwiatkowski DJ; Maki RG
J Clin Oncol; 2010 Feb; 28(5):835-40. PubMed ID: 20048174
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the AKT/mTOR Pathway Augments the Anticancer Effects of Sorafenib in Thyroid Cancer.
Yi H; Ye X; Long B; Ye T; Zhang L; Yan F; Yang Y; Li L
Cancer Biother Radiopharm; 2017 Jun; 32(5):176-183. PubMed ID: 28622037
[TBL] [Abstract][Full Text] [Related]
9. Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas).
Sanfilippo R; Jones RL; Blay JY; Le Cesne A; Provenzano S; Antoniou G; Mir O; Fucà G; Fumagalli E; Bertulli R; Stacchiotti S; Brahmi M; Grosso F; Dufresne A; Hindi N; Sbaraglia M; Gronchi A; Collini P; Dei Tos AP; Casali PG
Clin Cancer Res; 2019 Sep; 25(17):5295-5300. PubMed ID: 31217199
[TBL] [Abstract][Full Text] [Related]
10. Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
Aderhold C; Faber A; Umbreit C; Birk R; Weiss C; Sommer JU; Hörmann K; Schultz JD
Anticancer Res; 2015 Apr; 35(4):1951-9. PubMed ID: 25862847
[TBL] [Abstract][Full Text] [Related]
11. Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates.
Dickson MA; Schwartz GK; Antonescu CR; Kwiatkowski DJ; Malinowska IA
Int J Cancer; 2013 Apr; 132(7):1711-7. PubMed ID: 22927055
[TBL] [Abstract][Full Text] [Related]
12. Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors.
Sanfilippo R; Fabbroni C; Fucà G; Fumagalli E; Morosi C; Sbaraglia M; Gronchi A; Collini P; Dei Tos AP; Casali PG
Clin Cancer Res; 2020 Oct; 26(20):5534-5538. PubMed ID: 32605908
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant sirolimus for a large hepatic perivascular epithelioid cell tumor (PEComa).
Bergamo F; Maruzzo M; Basso U; Montesco MC; Zagonel V; Gringeri E; Cillo U
World J Surg Oncol; 2014 Feb; 12():46. PubMed ID: 24575738
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous inhibition of aberrant cancer kinome using rationally designed polymer-protein core-shell nanomedicine.
Chandran P; Gupta N; Retnakumari AP; Malarvizhi GL; Keechilat P; Nair S; Koyakutty M
Nanomedicine; 2013 Nov; 9(8):1317-27. PubMed ID: 23669368
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant or adjuvant sirolimus for malignant metastatic or locally advanced perivascular epithelioid cell tumors: two case reports.
Batereau C; Knösel T; Angele M; Dürr HR; D'Anastasi M; Kampmann E; Ismann B; Bücklein V; Lindner LH
Anticancer Drugs; 2016 Mar; 27(3):254-8. PubMed ID: 26645891
[TBL] [Abstract][Full Text] [Related]
16. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
Pignochino Y; Dell'Aglio C; Basiricò M; Capozzi F; Soster M; Marchiò S; Bruno S; Gammaitoni L; Sangiolo D; Torchiaro E; D'Ambrosio L; Fagioli F; Ferrari S; Alberghini M; Picci P; Aglietta M; Grignani G
Clin Cancer Res; 2013 Apr; 19(8):2117-31. PubMed ID: 23434734
[TBL] [Abstract][Full Text] [Related]
17. Malignant PEComa With Metastatic Disease at Diagnosis and Resistance to Several Chemotherapy Regimens and Targeted Therapy (m-TOR Inhibitor).
Machado I; Cruz J; Lavernia J; Rayon JM; Poveda A; Llombart-Bosch A
Int J Surg Pathol; 2017 Sep; 25(6):543-549. PubMed ID: 28459168
[TBL] [Abstract][Full Text] [Related]
18. Emerging therapeutic targets for synovial sarcoma.
Palmerini E; Paioli A; Ferrari S
Expert Rev Anticancer Ther; 2014 Jul; 14(7):791-806. PubMed ID: 24661286
[TBL] [Abstract][Full Text] [Related]
19. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
[TBL] [Abstract][Full Text] [Related]
20. CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
Devapatla B; Sharma A; Woo S
PLoS One; 2015; 10(9):e0139237. PubMed ID: 26414070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
